Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

ugh the oral route is not excluded as an option, targeted delivery, which could be developed with appropriate players in this field, could have the added benefit of avoiding unnecessary systemic exposure."

AR-709 is a novel DHFR inhibitor with an outstanding microbiological activity against streptococci in general and, importantly, against multi-drug resistant Streptococcus pneumoniae, the most relevant pathogen in community-acquired pneumonia. Moreover the compound has been shown to be highly effective in preclinical pneumonia models of infection both intravenously and by the oral route.

Arpida is completing the appropriate studies in order to initiate tolerability studies in humans.

About Streptococcus pneumoniae and pneumonia

Streptococcus pneumoniae is the most feared bacterium that causes pneumonia in the community setting. Since the first reports of Streptococcus pneumoniae resistance to penicillin in 1967, the number of multiple antibiotic resistant organisms has rapidly increased world-wide, reaching peaks of 80% in regions of some countries in 1998. In the USA, up to 40% of the bacterial strains causing these infections are resistant to at least one drug, and 15% are resistant to three or more commonly used drugs. Streptococci cause 500,000 cases of pneumonia each year, and 7 million cases of ear infections and sinusitis in the USA alone. Recently, epidemics of diseases caused by Streptococcus pneumoniae have reappeared in settings such as chronic care facilities, military camps and day care centers, a situation not seen since the pre-antibiotic era.

This increasing number of antibiotic-resistant pathogens is of specific concern to physicians in the area of respiratory tract infection. In the community setting, 67% of antibiotic use in adults and 87% in children is for the treatment of RTIs. The antibacterial market in the community settings is estimated at USD18 billion with pneumonia acquired in the community setting acc
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:7/24/2014)... Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased by ... Reported sales increased 5% which included a 1% benefit ... as reported (EPS) were $2.49, compared with $2.24 in ... an increase of 9% over the prior-year amount of ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... 28, 2011 Volcano Corporation (NASDAQ: VOLC ... therapy tools designed to enhance the treatment of coronary ... Leslie V. Norwalk, Esq., and Eric J. Topol, M.D., ... Ms. Norwalk currently serves as strategic counsel to EpsteinBeckerGreen, ...
... -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... the People,s Republic of China, today announced that it has ... Awards in the category of "Best Company in an Emerging ... on November 3, 2011 at the Grosvenor House hotel in ...
Cached Medicine Technology:Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors 2Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors 3China Biologic Nominated for the 2011 Scrip Award as Best Company in an Emerging Market 2China Biologic Nominated for the 2011 Scrip Award as Best Company in an Emerging Market 3
(Date:7/25/2014)... July 26, 2014 PersonalInjurySolicitorsIreland, a ... help to people who have suffered from a ... of both their new company, and a website, ... the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the ... focus of the company is always on the ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... 2014 Consuming too much salt? Overloaded ... , Read the labels! , Learn to decipher the ... relates to health during a "Healthy Eating for You: ... Humility House, 755 Ohltown Road, Austintown. , Registered dietician ... discussion and answer questions. , The presentation is ...
(Date:7/25/2014)... Island (PRWEB) July 25, 2014 Reproductive ... to announce that Dr. Kerri Luzzo, Lead Physician at ... Award" for her professional accomplishments in fertility care and ... , At the 10th Annual PBN Awards ceremony held ... Island, 40 of the most highly regarded, emerging leaders ...
(Date:7/25/2014)... US (PRWEB) July 25, 2014 ... provider of technology-enabled services for the financial, legal, ... its virtual data room business, Merrill DataSite, has ... Year” presented by GrowthBusiness at the M&A Awards ... recognize the achievements of entrepreneurs, management teams, advisors ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... interaction with cyclosporine could lead to fatal complications ... People taking the immunosuppressant cyclosporine should avoid consuming ... and possibly lead to deadly consequences, new research ... rats taking cyclosporine -- commonly used to help ...
... 25 NeuroVasx, Inc., a medical device company that ... stroke, announced today that it has received CE Mark ... is a minimally invasive device for the embolization of ... of an artery in the brain. If ruptured, aneurysms ...
... to Assist Processing Plants.SHREVEPORT, La., March 25 Since ... proven to be effective on the poultry processing line ... Salmonella, E. coli , and Listeria . ... help control Campylobacter by pre-screening birds for their current ...
... The 2008 Frost & Sullivan European ... is presented to Ferring Pharmaceuticals. The award ... providing no-needle injection for human growth hormone ... and ZOMAJET VISION X, innovative no-needle delivery ...
... March 25 /PRNewswire-Asia-FirstCall/ -- China Medical,Technologies, Inc. ... a leading China-based,medical device company that develops, ... announced that the Company received,quality testing certificate ... ,SPR System,) from one of the State ...
... March 25 Curemark, LLC, a drug research and ... announced today that the U.S. Food and Drug Administration ... application to initiate its pivotal Phase III clinical trial ... to begin Phase III clinical trials at multiple sites ...
Cached Medicine News:Health News:Licorice May Block Absorption of Organ Transplant Drug 2Health News:NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System 2Health News:SteriFx Inc. Provides 'Solutions' to Combat Campylobacter 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 3
... 45° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... The 45° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
... The Chalam 15° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
The Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens....
Medicine Products: